¿¬¼ö°­ÁÂ
Á¦34Â÷ ´ëÇѺÎÀÎÁ¾¾çÇÐȸ Ãá°èÇмú´ëȸ : 2019-04-26
Á¦34Â÷ ´ëÇѺÎÀÎÁ¾¾çÇÐȸ Ãá°èÇмú´ëȸ : 2019-04-26
±³À°ÀÏÀÚ : 2019-04-26
±³À°Àå¼Ò : ºÎ»ê·Ôµ¥È£ÅÚ Å©¸®½ºÅ»º¼·ë ¿Ü  
±³À°ÁÖÁ¦ : Á¦34Â÷ ´ëÇѺÎÀÎÁ¾¾çÇÐȸ Ãá°èÇмú´ëȸ
ÁÖÃÖ±â°ü : ´ëÇѺÎÀÎÁ¾¾çÇÐȸ
´ã´çÀÚ : ÀÌÇѳª
¿¬¶ôó : 02-512-5915  
À̸ÞÀÏ : gyncancer@gyncancer.or.kr      
±³À°Á¾·ù : »êºÎÀΰú      
Âü¼®¿¹»óÀοø : 400¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ºÎ»ê±¤¿ª½Ã
±³À°½Ã°£ : 16 ½Ã°£ 10ºÐ  
¼¼ºÎ¼ö°­·á : 80,000¿ø      
ºñ°í Àü¹®ÀÇ : 8¸¸¿ø Àü°øÀÇ : 6¸¸¿ø ¿¬±¸¿ø/°£È£»ç : 4¸¸¿ø ÁÂÀå,¿¬ÀÚ,¸¸65¼¼ÀÌ»ó : ¹«·á      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 04-26 Å©¸®½ºÅ»º¼·ë 07:30~08:00 Registration  .(.) 
±³À°½Ã°£ 04-26 Å©¸®½ºÅ»º¼·ë 08:00~08:15 Post LACC trial status in other countries  ÀÌÀ¯¿µ(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 04-26 Å©¸®½ºÅ»º¼·ë 08:15~08:30 KSGO position statement on MIS in patients with early cervical cancer  ±è¿ë¹ü(¼­¿ïÀÇ´ë) 
Åä·Ð 04-26 Å©¸®½ºÅ»º¼·ë 08:30~08:50 Discussion (°øûȸ)  () 
±âŸ 04-26 Å©¸®½ºÅ»º¼·ë 08:50~09:10 °³È¸»ç ¹× ¸í¿¹È¸¿øÁõ ¼ö¿©  ±è½Âö(ÀÌÈ­ÀÇ´ë) 
±âŸ 04-26 Å©¸®½ºÅ»º¼·ë 09:10~09:20 [Çмú´ë»ó] 1 topic  .(.) 
±âŸ 04-26 Å©¸®½ºÅ»º¼·ë 09:20~10:00 Plenary session 4 topics  .(.) 
±³À°½Ã°£ 04-26 Å©¸®½ºÅ»º¼·ë 10:00~10:10 KSGO-AOGIN young doctor program  AOGIN ¿¬¼ö»ý(.) 
Åä·Ð 04-26 Å©¸®½ºÅ»º¼·ë 10:10~10:20 Discussion  .(.) 
È޽Ġ04-26 Å©¸®½ºÅ»º¼·ë 10:20~10:40 Coffee break  .(.) 
±³À°½Ã°£ 04-26 Å©¸®½ºÅ»º¼·ë 10:40~11:10 LACC trial - impact in the US  Warner Huh(SGO President) 
±³À°½Ã°£ 04-26 Å©¸®½ºÅ»º¼·ë 11:10~11:40 Reappraisal of cervical adenocarcinoma treatments  Nobuo Yaegashi(Tohoku University Japan) 
±³À°½Ã°£ 04-26 Å©¸®½ºÅ»º¼·ë 11:40~12:10 TAGO clinical practice guidelines  Hung-Hsueh Chou(Chang Gung University Taiwan) 
±³À°½Ã°£ 04-26 Å©¸®½ºÅ»º¼·ë 12:10~12:40 Clonal expansion and diversification of cancer-associated mutations in endometriosis and normal endometrium  Takayuki Enomoto(Niigata University Japan / JGOG President) 
±³À°½Ã°£ 04-26 Å©¸®½ºÅ»º¼·ë 12:40~13:40 HPV test for primary screening for cervical cancer  Tay Sun Kuie(Singapore General Hospital Singapore) 
Åä·Ð 04-26 Å©¸®½ºÅ»º¼·ë B 13:40~15:20 10 topics each: 8min presentation/2min discussion  .(.) 
È޽Ġ04-26 Å©¸®½ºÅ»º¼·ë B 15:20~15:40 Coffee break  .(.) 
±³À°½Ã°£ 04-26 Å©¸®½ºÅ»º¼·ë B 15:40~16:00 Prediction of optimal cytoreductrive surgery in advanced ovarian cancer  ÀÌ´ëÇü(¿µ³²ÀÇ´ë) 
±³À°½Ã°£ 04-26 Å©¸®½ºÅ»º¼·ë B 16:00~16:20 Role of PARP inhibitor as front-line maintenance therapy in advanced ovarian cancer: SOLO-1  À¯ÇåÁ¾(Ãæ³²ÀÇ´ë) 
±³À°½Ã°£ 04-26 Å©¸®½ºÅ»º¼·ë B 16:20~16:40 Combination treatment of PAPR inhibitor with other therapies in ovarian cancer : benefit and risk  ÀÌÁ¤À±(¿¬¼¼ÀÇ´ë) 
Åä·Ð 04-26 Å©¸®½ºÅ»º¼·ë B 16:40~16:50 Discussion  .(.) 
±³À°½Ã°£ 04-26 Å©¸®½ºÅ»º¼·ë B 16:50~17:10 Treatment of ovarian cancer with PARP inhibitors: the importance of BRCA status  ±Çº´¼ö(ºÎ»êÀÇ´ë) 
±³À°½Ã°£ 04-26 Å©¸®½ºÅ»º¼·ë B 17:10~17:30 Real-world management of genetic counseling clinic in real practice  ±è¹Ì°æ(ÀÌÈ­ÀÇ´ë) 
±³À°½Ã°£ 04-26 Å©¸®½ºÅ»º¼·ë B 17:30~17:50 Updated KSGO position statement for genetic testing & management  ±è¹Ì¼±(Â÷ÀÇ´ë) 
Åä·Ð 04-26 Å©¸®½ºÅ»º¼·ë B 17:50~18:00 Discussion  .(.) 
Åä·Ð 04-26 Å©¸®½ºÅ»º¼·ë C 13:40~15:20 10 topics each: 8min presentation/2min discussion  .(.) 
È޽Ġ04-26 Å©¸®½ºÅ»º¼·ë C 15:20~15:40 Coffee break  .(.) 
±³À°½Ã°£ 04-26 Å©¸®½ºÅ»º¼·ë C 15:40~16:00 How to targeted therapy in platinum sensitive or resistance ovary cancer  ÀÌ¿ø¹«(ÇѾçÀÇ´ë) 
±³À°½Ã°£ 04-26 Å©¸®½ºÅ»º¼·ë C 16:00~16:20 Targeted agents and chemotherapy for endometrial cancer  ¼ÛÀçÀ±(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 04-26 Å©¸®½ºÅ»º¼·ë C 16:20~16:40 Immunotherapy combination for HPV related cancer  Çѽ¼ö(Áß¾ÓÀÇ´ë) 
Åä·Ð 04-26 Å©¸®½ºÅ»º¼·ë C 16:40~16:50 Discussion  .(.) 
±³À°½Ã°£ 04-26 Å©¸®½ºÅ»º¼·ë C 16:50~17:05 Key points of revised FIGO staging of cervical cancer 2018  ÀÌ´ë¿ì(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 04-26 Å©¸®½ºÅ»º¼·ë C 17:05~17:20 Impacts of revised FIGO staging 2018 on daily practice and research: Gynecologic Oncology  Á¶µ¿ÈÞ(ÀüºÏÀÇ´ë) 
±³À°½Ã°£ 04-26 Å©¸®½ºÅ»º¼·ë C 17:20~17:35 Impacts of revised FIGO staging 2018 on daily practice and research: Radiation Oncology  ±èÁØ¿ø(¿¬¼¼ÀÇ´ë ¹æ»ç¼±Á¾¾çÇаú) 
±³À°½Ã°£ 04-26 Å©¸®½ºÅ»º¼·ë C 17:35~17:50 Impacts of revised FIGO staging 2018 on daily practice and research: Cancer Epidemiology  ¿ø¿µÁÖ(±¹¸³¾Ï¼¾ÅÍ ±¹Á¦¾Ï´ëÇпø´ëÇб³ ¾Ï°ü¸®Çаú) 
±³À°½Ã°£ 04-26 Å©¸®½ºÅ»º¼·ë C 17:50~18:00 Discussion  .(.) 
±³À°½Ã°£ 04-26 ¿¡¸Þ¶öµå·ë 13:40~14:00 Fertility preservation in gynecologic oncology  ÃÖÁø¿µ(ÃæºÏÀÇ´ë) 
±³À°½Ã°£ 04-26 ¿¡¸Þ¶öµå·ë 14:00~14:20 Sentinel LN mapping in endometrial cancer  ¹é¹ÎÇö(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 04-26 ¿¡¸Þ¶öµå·ë 14:20~15:10 Update on clinical trial in gynecologic oncology  ½É½ÂÇõ(°Ç±¹ÀÇ´ë) 
Åä·Ð 04-26 ¿¡¸Þ¶öµå·ë 15:10~15:20 Discussion  .(.) 
È޽Ġ04-26 ¿¡¸Þ¶öµå·ë 15:20~15:40 Coffee break  .(.) 
±³À°½Ã°£ 04-26 ¿¡¸Þ¶öµå·ë 15:40~16:10 IV management on gynecologic cancer  ±è»óÈñ(»ï¼º¼­¿ïº´¿ø Àü¹®°£È£»ç) 
±³À°½Ã°£ 04-26 ¿¡¸Þ¶öµå·ë 16:10~16:40 Hypersensitivity management  À¯¼±¿µ(¼­¿ï¾Æ»êº´¿ø Àü¹®°£È£»ç) 
±³À°½Ã°£ 04-26 ¿¡¸Þ¶öµå·ë 16:40~17:10 OCN guidance  Á¶ÇýÁø(ÀÌ´ë¼­¿ïº´¿ø Àü´ã°£È£»ç) 
±³À°½Ã°£ 04-26 ¿¡¸Þ¶öµå·ë 17:10~17:40 Decision on life-sustaining treatment in gynecologic oncology  ¿¹º´ÀÏ(¿¬¼¼¿øÁÖÀÇ´ë ÀÇÇб³À°ÇÐ) 
Åä·Ð 04-26 ¿¡¸Þ¶öµå·ë 17:40~18:00 Discussion  .(.) 
  • ÃßõÇϱâ
Tip. ±³À°ÀÏÁ¤Àº ±³À°±â°üÀÇ »çÁ¤¿¡ µû¶ó º¯°æµÉ ¼ö ÀÖÀ¸¹Ç·Î »çÀü¿¡ ¹Ýµå½Ã ±³À°±â°üÀ¸·Î ¹®ÀÇÇÏ¿© È®ÀÎ ¹Ù¶ø´Ï´Ù.
¡å
ÀÛ¼ºÀÚ   ºñ¹Ð¹øÈ£
 
¿¬¼ö°­Á ÁÖ°£º£½ºÆ®
Á¦¸ñ

[¼­¿ï] 2024 ½ÉÀå»öÀü¿¬±¸È¸ ½ÉÆ÷Áö¿ò : 2024-03-30

±³À°ÀÏÀÚ : 2024-03-30 ±³À°Àå¼Ò : »ï¼º¼­¿ïº´¿ø ÀÏ¿ø¿ª»ç Bµ¿ 9Ãþ È÷Æ÷Å©¶óÅ×½ºÈ¦ ±³À°ÁÖÁ¦ : 2024 ½ÉÀå»öÀü¿¬±¸È¸ ½ÉÆ÷Áö¿òÁÖÃÖ±â°ü : ´ëÇѳúÁ¹ÁßÇÐȸ ½ÃÇà±â°ü(ÁöºÎ/

Ãßõ¼ö : 0 , Á¶È¸¼ö : 1,206 , ´ñ±Û¼ö : 0

[ºÎ»ê] ´ëÇÑ°ñÀýÇÐȸ Á¦50Â÷ Çмú´ëȸ(1ÀÏÂ÷) : 2024-04-26

±³À°ÀÏÀÚ : 2024-04-26 ±³À°Àå¼Ò : ·Ôµ¥È£ÅÚ ºÎ»ê ±³À°ÁÖÁ¦ : ´ëÇÑ°ñÀýÇÐȸ Á¦50Â÷ Çмú´ëȸ(1ÀÏÂ÷)ÁÖÃÖ±â°ü : ´ëÇÑ°ñÀýÇÐȸ ´ã´çÀÚ : Á¤À¯Áø ¿¬¶ôó : 031-551

Ãßõ¼ö : 0 , Á¶È¸¼ö : 1,011 , ´ñ±Û¼ö : 0

[ºÎ»ê] 2024 ºÎ»ê¿ï»ê°æ³²Ä¡¸ÅÇÐȸ Ãá°èÇмú´ëȸ : 2024-03-16

±³À°ÀÏÀÚ : 2024-03-16 ±³À°Àå¼Ò : ÇØ¿î´ë¹éº´¿ø 5Ãþ ´ë°­´ç ±³À°ÁÖÁ¦ : 2024 ºÎ»ê¿ï»ê°æ³²Ä¡¸ÅÇÐȸ Ãá°èÇмú´ëȸÁÖÃÖ±â°ü : ´ëÇÑÄ¡¸ÅÇÐȸ ½ÃÇà±â°ü(ÁöºÎ/°ú) : ºÎ»ê¿ï

Ãßõ¼ö : 0 , Á¶È¸¼ö : 1,210 , ´ñ±Û¼ö : 0

[ºÎ»ê] 2024 ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ºÎ¿ï°æÁöȸ Áú°ü¸® ½ÉÆ÷Áö¿ò : 2024-03-30

±³À°ÀÏÀÚ : 2024-03-30 ±³À°Àå¼Ò : ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ BPEX 5Ãþ ÄÁÆÛ·±½ºÈ¦ ±³À°ÁÖÁ¦ : 2024 ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ºÎ¿ï°æÁöȸ Áú°ü¸® ½ÉÆ÷Áö¿òÁÖÃÖ±â°ü : ´ëÇÑ

Ãßõ¼ö : 0 , Á¶È¸¼ö : 1,214 , ´ñ±Û¼ö : 0

[´ë±¸] Á¦27Â÷ ´ëÇѽÉÀåÇÐȸ ´ë±¸°æºÏÁöȸ ÀÓ»ó½ÉÀåÇÐ ¿¬¼ö°­Á : 2024-03-24

±³À°ÀÏÀÚ : 2024-03-24 ±³À°Àå¼Ò : ´ë±¸ ÀÎÅÍºÒ°í ¸¸Ã̵¿ ÄÁº¥¼ÇȦ 2Ãþ ±³À°ÁÖÁ¦ : Á¦27Â÷ ´ëÇѽÉÀåÇÐȸ ´ë±¸°æºÏÁöȸ ÀÓ»ó½ÉÀåÇÐ ¿¬¼ö°­ÁÂÁÖÃÖ±â°ü : ´ëÇѽÉÀåÇÐȸ ½ÃÇà±â

Ãßõ¼ö : 0 , Á¶È¸¼ö : 1,251 , ´ñ±Û¼ö : 0